Contrast-Enhanced Cardiac Magnetic Resonance Imaging With a Manganese-Based Alternative to Gadolinium for Tissue...

Area of Science:

• Cardiovascular Imaging
• Medical Contrast Agents
• Biomedical Engineering

Background:

• Late gadolinium enhancement cardiac MRI is standard for characterizing myocardial infarction.
• Gadolinium contrast agents pose risks for patients with renal insufficiency and can cause tissue deposition.
• There is a clinical need for safer MRI contrast agents, especially for patients with kidney issues.

Purpose of the Study:

• To evaluate the efficacy of a novel manganese-based contrast agent (RVP-001) as an alternative to gadolinium-based agents for myocardial infarction assessment.
• To compare the accuracy of RVP-001 with traditional late gadolinium enhancement MRI in measuring infarct size and transmurality.

Main Methods:

• Cardiac MRI was performed 3 days after ischemia/reperfusion in the left anterior descending coronary artery.
• Contrast agents (RVP-001 and gadolinium) were administered alternately with washout periods.
• Infarct size and transmurality were measured using Segment Medviso software and analyzed with Bland-Altman methods.

Main Results:

• Mean infarct size and transmurality measurements using RVP-001 were comparable to those obtained with late gadolinium enhancement.
• Bland-Altman analysis showed minimal bias (0.13 mL) for RVP-001 in gross infarct size measurement.
• No significant differences were observed between the two contrast agents in lesion evaluation.

Conclusions:

• The manganese-based contrast agent RVP-001 is effective for assessing myocardial infarction location, size, and transmurality.
• RVP-001 presents a potential alternative to gadolinium-based contrast agents, particularly for patients with renal insufficiency.
• This agent may overcome safety concerns associated with gadolinium deposition and contraindications in renal impairment.